NEW YORK, March 14, 2019 – Levi & Korsinsky, LLP announces a class action has commenced on behalf of shareholders who purchased or otherwise acquired securities of Amarin Corporation (“Amarin”) (NASDAQGM: AMRN) between September 24, 2018 and November 9, 2018. The Amarin class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information about the AMRN class action go to: https://www.zlk.com/pslra-1/amarin-corporation-loss-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The AMRN class action alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in Amarin you have until April 23, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com